Fertility and sterility最新文献

Importance: Findings from several high profile meta-analyses have raised concerns about an ongoing global decline in sperm concentration and male fertility. However, these studies exhibit considerable heterogeneity in key variables including study population, methodology, fertility status, and geographic region.

Objective: To perform a systematic review and meta-analysis exploring temporal trends in sperm concentration among fertile men and men unselected for fertility status in the United States.

Data sources: A literature search performed in Scopus and PubMed databases for studies published between 1970 and 2023. Additional studies were included from citations of prior global meta-analyses and reviews evaluating temporal trends in sperm count.

Study selection and synthesis: Studies were included if they presented original data on sperm concentration in US men without known infertility from 1970 to 2023. Aggregate data were assessed across all study populations, with additional subgroup analyses stratified by fertility status and US region.

Main outcomes: Weighted generalized linear models were generated to evaluate the association between mean sperm concentration and sample collection year.

Results: A total of 874 articles were screened, with 58 meeting the inclusion criteria. These represented 75 unique study populations totaling 11,787 men in the United States. Across all study populations, no change in sperm concentration was observed between 1970 and 2018 in unadjusted models (β = 0.14 million/mL per year). When adjusting for US region, no statistically significant decline in sperm concentration was seen. When adjusting for both region and fertility status, a modest annual decline was observed to meet statistical significance (β = -0.35 million/mL per year). Of the 49 study populations reporting adequate data to determine mean total sperm count, there was a significant increase in total sperm count of 2.9 million per year between 1970 and 2018. Subgroup analysis found no statistically significant change in mean sperm concentration among any US census region or fertility status cohort.

Conclusion and relevance: In contrast to prior global studies, this analysis suggests no clinically significant decline in sperm concentration among confirmed fertile men and the general male US population without known infertility. Although these findings provide some reassurance against a widespread rapid decline, further studies are necessary to better understand this important topic.

Objective: To determine whether we can safely and successfully transplant an ovary tissue allograft from a nonidentical donor to her Turner syndrome sister.

Design: Transplantation of cryopreserved ovary tissue, as well as fresh transplantation of ovarian tissue between identical twins, is now well established with numerous reported successful cases. However, there have not yet been any ovary transplants between nonidentical women requiring immunosuppression (ovary allotransplant). This could be a much more common indication for ovary tissue transplantation if safe and reliable immunosuppression were available.

Patient(s): A 20-year-old amenorrheic woman with nonmosaic 45-XO Turner syndrome requested ovary tissue transplantation from her fertile 22-year-old 46-XX sister. They were an human leukocyte antigens match but were ABO incompatible, a well-known contra-indication to solid tissue or organ transplantation. The Turner syndrome sister strongly preferred to be able to become pregnant naturally without donor egg in vitro fertilization and to avoid hormone replacement therapy. In her religious group, that would also be important for finding a marital match. Despite the poor prognosis associated with ABO incompatibility, an ovary from her 22-year-old nonidentical fertile sister was transplanted to her employing the immunosuppression protocol now used for kidney transplant patients in our centers at Washington University and Johns Hopkins.

Intervention(s): Not applicable.

Main outcome measure(s): Post operatively at 5 months she developed normal monthly menstrual ovarian function, and she became spontaneously pregnant with a normal infant girl. The relation between her postoperation follicle stimulating hormone and antimüllerian hormone levels continue to support the theory that tissue pressure controls primordial follicle recruitment. The fact that ABO incompatibility did not prevent success suggests that diffusion and not revascularization may be all that is required for successful long-term ovarian cortex transplant survival with spontaneous pregnancy.

Result(s): Ovary allotransplantation with safe immunosuppression allows natural conception, and also normal hormone function obviates the need for hormone replacement therapy. Orthotopic placement of the graft and surgical technique is critical for natural conception and a higher pregnancy rate.

Conclusion(s): Allotransplantation requiring safe immunosuppression, if successful, maybe a much more commonly used indication for ovary transplantation in the future than frozen ovary grafts or grafts between identical twins.

Objective: To determine whether industry payments to physicians are associated with a difference in assisted reproductive technology practices and outcomes.

Design: Retrospective cohort.

Patient(s): Patients undergoing asissted reproduction.

Intervention(s): Industry payments reported to the Open Payments 2020 database.

Main outcome measure(s): The live birth rate, frozen embryo transfer (FET) rate, intracytoplasmic sperm injection (ICSI) rate, preimplantation genetic testing (PGT) rate, and percentage of patients aged >40 years were obtained from the Centers for Disease Control and Prevention 2020 database. Linear regression analysis was performed comparing the percentage of physicians per center receiving industry payments to clinic-level outcomes.

Result(s): A total of 873 reproductive endocrinology and infertility physicians received payments in the 2020 database. At least one physician received a payment in 80.5% (437/543) of in vitro fertilization centers. Of 1,724 reproductive endocrinology and infertility physicians, 873 (50.6%) received at least one payment in 2020. The live birth, ICSI, FET, and PGT rates and percentage of patients aged >40 years did not significantly differ between centers by percentage of physicians receiving industry payments. However, in the subanalysis of 99 large centers (defined as ≥5 physicians), each increase in the percentage of physicians receiving industry payments was associated with increases of 0.20% (95% confidence interval, 0.02-0.39) and 0.14% (95% confidence interval, 0.05-0.24) in the PGT and FET rates, respectively. The live birth, ICSI rates and percentage of patients aged >40 years were not associated with increased industry payment rates to physicians.

Conclusion(s): Industry payments were not associated with differences in in vitro fertilization center outcomes overall. However, large centers with more physicians receiving industry payments may be more likely to use additional procedures such as PGT and FET, without improvement in the final outcomes such as the live birth rate. Further research is needed to determine whether these differences reflect the industry payment influence vs. individual center/provider practice habits in larger practices.

Objective: To evaluate the impact of preimplantation genetic testing for aneuploidy (PGT-A) on first transfer live birth rate (LBR) and cumulative LBR (CLBR) in donor oocyte in vitro fertilization (IVF) cycles.

Design: Retrospective cohort study of the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database.

Setting: Fertility centers reporting to Society for Assisted Reproductive Technology.

Patient(s): A total of 11,348 fresh and 7,214 frozen-thawed donor oocyte IVF cycles were analyzed.

Intervention(s): The first reported donor stimulation cycle per patient between January 1, 2014, and December 31, 2015, and all linked embryo transfer cycles between January 1, 2014, and December 31, 2016, were included in the study.

Main outcome measure(s): Live birth rate was compared for patients using fresh and frozen-thawed donor oocytes, with or without PGT-A. Logistic regression models were adjusted for age, body mass index, gravidity, infertility etiology, and prior IVF cycles.

Result(s): Among patients who had blastocysts available for transfer or PGT-A, the use of PGT-A was associated with a decreased first transfer LBR (46.9 vs. 53.2%) and CLBR (58.4 vs. 66.6%) in fresh oocyte donor cycles compared with no PGT-A. Live birth rate in frozen-thawed oocyte donor cycles with PGT-A were nominally higher than those without PGT-A (48.3% vs. 40.5%) but were not statistically significant in multivariable logistic regression models. Early pregnancy loss was not significantly different with and without PGT-A. Multiple gestation, preterm birth, and low birth weight infants were all reduced with the addition of PGT-A in fresh donor oocyte cycles, although these outcomes were not significantly different when comparing single embryo transfers in fresh oocyte cycles and also not significantly different among frozen-thawed donor oocyte cycles.

Conclusion(s): Preimplantation genetic testing for aneuploidy in fresh oocyte donor cycles was associated with decreased LBR and CLBR, whereas effects on frozen-thawed oocyte donor cycles were clinically negligible. Obstetric benefits associated with PGT-A in fresh donor cycles appear linked to increased single embryo transfer.

Aromatase inhibitors, particularly letrozole (LZ), are now established as first-line ovulation induction agents, offering an effective ovarian stimulation strategy to enhance outcomes of intrauterine insemination. In recent years, they have also emerged as potentially valuable adjuvants to gonadotropin ovarian stimulation for in vitro fertilization, particularly in fertility preservation in women with estrogen-responsive cancers. Their primary mechanism of action is to reduce the circulating estrogen levels by inhibiting androgen aromatization. Recent studies have provided evidence that this property may confer therapeutic advantages in other patients undergoing in vitro fertilization. In this study, evidence supporting the role of adjuvant LZ in poor responders, as a moderator of ovarian hyperstimulation syndrome symptoms, and an agent for improving the luteal phase after ovarian stimulation is reviewed. The use of LZ for endometrial preparation in the frozen-thawed embryo transfer cycle is also considered.